Literature DB >> 7796858

Endothelium-dependent contraction induced by acetylcholine in isolated rat renal arteries.

Y Nishimura1, H Usui, K Kurahashi, A Suzuki.   

Abstract

We investigated whether or not acetylcholine elicited an endothelium-dependent contraction and whether an arachidonic acid metabolite was involved in the acetylcholine-induced contraction in ring preparations of rat renal arteries. Acetylcholine (0.1-100 microM) caused a transient contraction in endothelium-intact arteries in a concentration-dependent manner. The contraction induced by acetylcholine (10 microM) was enhanced by pretreatment with NG-nitro-L-arginine (100 microM), a nitric oxide synthase inhibitor, and was abolished by mechanical removal of the endothelium. Atropine (0.1 microM), quinacrine (1 and 3 microM), manoalide (0.1 and 1 microM), aspirin (1 and 10 microM), indomethacin (30 and 300 nM), ONO-3708 (9,11-dimethyl-methane-11,12-methano-13,14-dihydro-13-aza-14- oxo-15(beta)-cyclophenyl-omega-pentenor-thromboxane A2 L-arginine salt) (10 nM), S-1452 (calcium (5Z)-1R,2S,3S,4S-7-[3-phenylsulphonyl-aminobicyclo[2.2.1]hep t-2yl]-5- heptenoate hydrate) (3 nM) and SQ29,548 ([1S- [1 alpha,2 beta(5Z),3 beta,4 alpha]]-7-[3-[[2-[(phenylamino) carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoi++ + c acid) (3 and 10 nM), but not hexamethonium (1 microM), OKY-046 (sodium (E)-3-[4-(1- imidazolylmethyl)phenyl]-2-propenoic acid hydrochloride monohydrate) (100 microM) and CS-518 (sodium 2-(1-imidazolylmethyl)-4,5- dihydrobenzo[b]thiophene-6-carboxylate) (10 microM) significantly attenuated the acetylcholine (10 microM)-induced endothelium-dependent contractions in renal arteries pretreated with NG-nitro-L-arginine. These findings suggest that acetylcholine causes endothelium-dependent contraction by stimulation of muscarinic receptors in rat renal arteries, and that an arachidonic acid metabolite(s) of the cyclooxygenase pathway is involved in this endothelium-dependent contraction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7796858     DOI: 10.1016/0014-2999(95)00023-e

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Endothelial dysfunction: a strategic target in the treatment of hypertension?

Authors:  Eva H C Tang; Paul M Vanhoutte
Journal:  Pflugers Arch       Date:  2010-02-02       Impact factor: 3.657

2.  Endothelium-derived factors and hyperpolarization of the carotid artery of the guinea-pig.

Authors:  C Corriu; M Félétou; E Canet; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  Thrombin causes endothelium-dependent biphasic regulation of vascular tone in the porcine renal interlobar artery.

Authors:  D N Derkach; E Ihara; K Hirano; J Nishimura; S Takahashi; H Kanaide
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

4.  The mechanism of bradykinin-induced endothelium-dependent contraction and relaxation in the porcine interlobar renal artery.

Authors:  E Ihara; K Hirano; D N Derkach; J Nishimura; H Nawata; H Kanaide
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

5.  Hydrogen peroxide is an endothelium-dependent contracting factor in rat renal artery.

Authors:  Yu-Jing Gao; Robert M K W Lee
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

6.  Thapsigargin-induced endothelium-dependent triphasic regulation of vascular tone in the porcine renal artery.

Authors:  E Ihara; K Hirano; J Nishimura; H Nawata; H Kanaide
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

7.  Hypertension and the absence of EDHF-mediated responses favour endothelium-dependent contractions in renal arteries of the rat.

Authors:  F S Michel; G S Man; R Y K Man; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

Review 8.  Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins.

Authors:  Sameer Ansar; Juraj Koska; Peter D Reaven
Journal:  Cardiovasc Diabetol       Date:  2011-07-07       Impact factor: 9.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.